F6Publishing

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Articles in Press

11/17/2023 8:49:01 AM | Browse: 35 | Download: 4

Publication Name	World Journal of Diabetes
Manuscript ID	88354
Country/Territory	China

Category

Endocrinology & Metabolism

Manuscript Type

Basic Study

Article Title

Empagliflozin ameliorates diabetic cardiomyopathy probably via activating AMPK/PGC-1a and inhibiting the RhoA/ROCK pathway

Manuscript Source

Unsolicited Manuscript

All Author List

Na Li, Qiu-Xiao Zhu, Gui-Zhi Li, Ting Wang and Hong Zhou

Funding Agency and Grant Number

Funding Agency	Grant Number
Health Commission of Hebei Province	20210196
S＆T Program of Hebei	22377726D

Corresponding Author

Hong Zhou, PhD, Chief Physician, Doctor, Department of Endocrinology, The Second Hospital of Hebei Medical University, No. 215, Heping West Road, Shijiazhuang 050000, Hebei Province, China. zhoubs2013@163.com

Key Words

Empagliflozin; Diabetic cardiomyopathy; AMPK; ROCK; Apoptosis; Oxidative stress

Core Tip

We established a diabetic cardiomyopathy model in db/db mice and treated the mice with empagliflozin for 8 wk, and found that empagliflozin observably improved cardiac function in diabetic mice, which was maybe related to activation of AMP-activated protein kinase (AMPK)/peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1a) and inhibition of the RhoA/ROCK pathway. In order to exclude the effects of metabolic improvement on the heart in vivo, in vitro experiment in high glucose conditions was performed. The results confirmed that the anti-oxidative stress and anti-apoptotic effects of empagliflozin on cardiomyocytes were achieved by activating AMPK/PGC-1a and inhibiting ROCK. Furthermore, the effects were independent of sodium-glucose cotransporter (SGLT)2 inhibition as no SGLT2 expression was detected on cardiomyocytes.

Citation

Li N, Zhu QX, Li GZ, Wang T, Zhou H. Empagliflozin ameliorates diabetic cardiomyopathy probably via activating AMPK/PGC-1 and inhibiting the RhoA/ROCK pathway. World J Diabetes 2023; In press

Received

2023-09-21 13:29

Peer-Review Started

2023-09-21 13:30

To Make the First Decision

Return for Revision

2023-10-10 08:48

Revised

2023-10-20 11:50

Second Decision

2023-11-14 01:15

Accepted by Journal Editor-in-Chief

Accepted by Company Editor-in-Chief

2023-11-17 08:49

Articles in Press

2023-11-17 08:49

Publication Fee Transferred

Edit the Manuscript by Language Editor

2023-11-13 02:53

Typeset the Manuscript

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Assistant Editor	Assistant Editor
Science Editor	Cong Lin
Reviewer Code	06139840, 02817134, 02991481, and 02817134
Editorial Director
Journal Chief Editor
Company Chief Editor	Jin-Lei Wang
Language Editor	Tian-Qi Wang
Production Editor
Responsible Production Editor
Responsible Science Editor
Proofing Editorial Director	Jin-Lei Wang
Proofing Editor-in-Chief	Lian-Sheng Ma